Skip to main content
Cardiolucent

Condition

Amyloid Heart Disease

Infiltrative cardiomyopathy that is now treatable when identified early.

Amyloid heart disease, or cardiac amyloidosis, occurs when misfolded protein deposits infiltrate the heart muscle, causing it to stiffen and gradually fail. The two main forms relevant to cardiology are transthyretin amyloidosis (ATTR), which can be hereditary or develop with aging, and light-chain amyloidosis (AL), which is a blood-related condition. Until recently, cardiac amyloidosis was considered untreatable, but new therapies — particularly tafamidis for transthyretin disease — have transformed the outlook for many patients. The diagnosis is often missed because the symptoms overlap with more common causes of heart failure. Dr. Kedan looks for the suggestive clues actively and pursues definitive testing when amyloidosis fits the pattern.

What Cardiolucent Evaluates

  • Detailed history including carpal tunnel surgery, neuropathy, autonomic symptoms, and family history
  • Echocardiography with strain imaging looking for the characteristic apical sparing pattern
  • EKG voltage and conduction analysis
  • Cardiac MRI in coordination with Cedars-Sinai when indicated
  • Serum and urine free light chains and immunofixation to screen for AL amyloidosis
  • Bone-tracer cardiac scintigraphy (PYP scan) for ATTR diagnosis
  • Hematology and amyloidosis-center referral when AL is suspected

Common Symptoms

  • Progressive shortness of breath and exercise intolerance
  • Leg swelling and weight gain from fluid retention
  • Atrial fibrillation, often new in onset
  • Bilateral carpal tunnel syndrome, sometimes years before cardiac symptoms
  • Lumbar spinal stenosis
  • Peripheral neuropathy and autonomic symptoms (orthostatic hypotension, GI dysmotility)
  • Easy bruising or periorbital purpura in AL amyloidosis
  • Disproportionate intolerance of standard heart failure medications

Risk Factors

  • Age over 65 (for wild-type ATTR)
  • Family history of amyloidosis or hereditary cardiac disease
  • Specific TTR gene variants more common in certain populations
  • Plasma cell dyscrasias such as multiple myeloma or MGUS (for AL)
  • Male sex (for wild-type ATTR)

How Cardiolucent Approaches Treatment

Treatment is type-specific. ATTR amyloidosis is now treated with tafamidis and newer agents that stabilize or silence the abnormal protein, and these therapies meaningfully extend survival when started early. AL amyloidosis is treated by hematology-oncology with regimens that target the underlying plasma cell clone. Heart failure management is supportive but requires special care because amyloid hearts often tolerate standard heart failure medications poorly. Dr. Kedan coordinates with hematology, amyloidosis centers, and the Cedars-Sinai infiltrative cardiomyopathy program for both diagnosis and ongoing management.

Common Questions

Frequently Asked Questions

What is amyloid heart disease?
Amyloid heart disease is infiltration of the heart muscle by misfolded protein fibrils called amyloid. The deposits make the muscle stiff and thickened, impairing both filling and contraction over time.
What are the different types?
The two main cardiac types are transthyretin amyloidosis (ATTR), which can be hereditary or develop with aging (wild-type), and light-chain amyloidosis (AL), which arises from a plasma cell disorder. Identifying the type is essential because the treatments and prognosis differ dramatically.
Why is amyloidosis often missed?
The symptoms — shortness of breath, swelling, fatigue, atrial fibrillation — overlap with much more common causes of heart failure, and the characteristic clues on echocardiogram are easy to overlook without active suspicion. Carpal tunnel syndrome, spinal stenosis, and autonomic symptoms are often present for years before the cardiac diagnosis.
How is amyloidosis diagnosed?
Echocardiography with strain imaging often shows a characteristic 'apical sparing' pattern. Serum and urine testing rule out the AL form. A bone-tracer cardiac scan (PYP scan) is highly accurate for ATTR amyloidosis, often allowing diagnosis without biopsy. Cardiac MRI may add additional information.
Is amyloid heart disease treatable?
Yes — and this is the most important shift in recent years. ATTR amyloidosis is now treated with disease-modifying medications that stabilize or silence the abnormal protein, meaningfully extending survival. AL amyloidosis is treated by hematology-oncology with targeted regimens. Early diagnosis substantially improves outcomes.
Why might standard heart failure medications not work well?
The stiff, infiltrated amyloid heart often does not tolerate standard heart failure medications like beta-blockers and ACE inhibitors as well as other cardiomyopathies do. Diuretics are usually the mainstay of symptom relief, but they must be carefully balanced because patients can be sensitive to volume changes.
Should my family be screened?
If hereditary ATTR is identified, first-degree relatives should be offered genetic testing and surveillance. The age at which symptoms develop can vary widely, but knowing the gene status allows early monitoring and earlier treatment when appropriate.
What does follow-up look like?
Patients on disease-modifying therapy are followed with periodic echocardiography, biomarkers (troponin and NT-proBNP), and clinical assessment. Dr. Kedan integrates this with the broader amyloidosis care team, including hematology when relevant.
What does Cardiolucent do differently for amyloidosis?
Dr. Kedan actively looks for the clues to amyloidosis rather than treating it as a zebra. POCUS and strain imaging at the visit, extended appointment lengths, and coordination with hematology and Cedars-Sinai infiltrative cardiomyopathy specialists support timely diagnosis and treatment.
How do I schedule a consultation?
Call (310) 304-5555 or use the contact form to schedule with Dr. Kedan at the Beverly Hills office. Cardiolucent does not bill Medicare or insurance; a detailed superbill is provided for any out-of-network reimbursement.

Explore

Related Conditions

Suspect amyloid heart disease in yourself or family?

Schedule a consultation with Dr. Kedan in Beverly Hills.
Schedule an Appointment

Medical Disclaimer

The information on this site is for general educational purposes only and is not medical advice, diagnosis, or treatment. Reading this site does not create a doctor–patient relationship. Always consult a qualified healthcare professional for personal guidance. If this is an emergency, call 911. Mentions of medications, devices, or procedures are informational and not endorsements. Full medical disclaimer.

†Some listed indications involve investigational/off-label use. Learn more.